Stock Groups

U.S. should review drugmakers’ opioid settlement tax breaks

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. REUTERS/Brendan McDermid/File Photo/File Photo

WASHINGTON, (Reuters) – The U.S. Justice and Treasury Departments need to review tax deductions made by four drugmakers in connection with their $26 billion opioid settlement. This was the U.S. House Oversight and Reform Committee stated Monday.

In a March 10-dated letter, lawmakers requested that the departments examine tax cuts taken by the department. Cardinal Health Inc (NYSE:), McKesson Corp (NYSE:), AmerisourceBergen (NYSE:) Corp and Johnson &Johnson.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]